British Journal of Pharmacology – Latest Impact Factor, Rankings & 2025 Editorial Changes
The British Journal of Pharmacology (BJP) stands as a premier platform for high-quality research in pharmacology, toxicology, and pharmaceutics. For researchers, clinicians, and academicians worldwide, BJP offers a respected space to disseminate original studies, reviews, commentaries, and correspondence, bridging basic science and translational pharmacological research
Get to know about British Journal of Pharmacology (BJP) aim and scope of BJP, its ranking and Impact Factor, key metrics, top research topics, indexing databases, publication timelines, submission process, acceptance rate, and the 2025 editorial changes.
Aim and Scope of British Journal of Pharmacology
The British Journal of Pharmacology (BJP) actively publishes high-quality, peer-reviewed research in Pharmacology, Toxicology, and Pharmaceutics. The journal provides a platform for authors to share original research, reviews, commentaries, and correspondence, covering both basic and translational pharmacological studies. John Wiley & Sons, Inc., one of the world’s leading academic publishers, publishes the journal.
Journal uses ISSN numbers 0007-1188 (print) and 1476-5381 (online) to identify its publications. According to Scopus, BJP holds a SCImago Journal Rank (SJR) of 2.344, demonstrating its strong influence and high visibility in pharmacology. The journal indexes articles in major databases such as PubMed/MEDLINE, SCIE, SSCI, and Scopus, ensuring that research reaches a global audience.
Clarivate’s Journal Citation Reports (JCR) indexes BJP in the Science Citation Index Expanded (SCIE), and the journal holds a significant Impact Factor, which authors often consider when evaluating its influence.
BJP employs a rigorous peer-review process and maintains an average review time, which varies depending on the type of submission and editorial workflow. While the journal does not charge standard Article Processing Charges (APC) for subscription-based publishing, authors who choose open access must pay Wiley’s APC fees. The journal maintains a competitive acceptance rate, reflecting its commitment to publishing high-quality research.
Overall, the British Journal of Pharmacology actively establishes itself as a top-tier journal, offering researchers a respected platform to disseminate impactful pharmacological research worldwide.
British Journal of Pharmacology Ranking and Impact Factor
- Impact Factor: 7.7
- 5-Year JIF: 7.3
- SJR (SCImago Journal Rank): 2.344
- Quartile: Q1
The British Journal of Pharmacology (BJP) consistently ranks among the top pharmacology journals worldwide. In the latest data, the journal achieves an Impact Factor (IF) of 7.7, with a 5-Year Impact Factor of 7.3, demonstrating that its articles continue to attract citations over an extended period. Its SCImago Journal Rank (SJR) stands at 2.344, and it occupies the Q1 quartile, placing it within the top 25% of journals in pharmacology.
Clarivate’s Journal Citation Reports (JCR) released the latest Impact Factor list in June 2025, confirming BJP’s status as a high-impact journal. The Impact Factor measures how frequently the average article in a journal is cited in a particular year, allowing authors, researchers, and institutions to assess the journal’s influence, relevance, and academic reach.
The Impact Factor originated with Eugene Garfield, the founder of the Institute for Scientific Information (ISI) in Philadelphia. Starting in 1975, ISI calculated Impact Factors yearly for journals listed in the Journal Citation Reports (JCR). Thomson Scientific & Healthcare acquired ISI in 1992, rebranding it as Thomson ISI. In 2018, Thomson Reuters spun off and sold ISI to Onex Corporation and Baring Private Equity Asia, which established Clarivate to continue publishing the JCR and calculating Impact Factors for journals globally.
By maintaining an Impact Factor of 7.7 alongside strong bibliometric indicators such as SJR and Q1 ranking, the British Journal of Pharmacology provides researchers with a prestigious platform to publish high-impact pharmacology research. Its consistent performance demonstrates the journal’s influence in advancing scientific knowledge and its critical role as a reference point for both basic and translational pharmacological studies.
British Journal of Pharmacology – Key Metrics Overview
| Metric | Details |
|---|---|
| Journal Title | British Journal of Pharmacology |
| Publisher | John Wiley and Sons Inc |
| ISSN | 1476-5381, 0007-1188 |
| Journal Scope | Pharmacology, Toxicology, Pharmaceutics |
| Country of Publisher | United States |
| Scopus CiteScore | 14.4 |
| Scopus Coverage | 1966–2025 |
| H-Index | 252 |
| SJR (SCImago Journal Rank) | 2.344 |
| Quartile | Pharmacology (Q1) |
| Open Access | No |
Top Research Topics at the British Journal of Pharmacology
The British Journal of Pharmacology (BJP) is a leading journal in the fields of pharmacology, toxicology, and pharmaceutics, and it publishes high-quality research across a wide spectrum of biomedical sciences. The journal’s research focus spans several key areas, reflecting both foundational and applied studies in medicine and pharmacology.
1. Internal Medicine
Internal medicine is a significant focus at BJP, accounting for approximately 53.64% of published research. Within this field, the journal addresses topics such as agonists, antagonists, stimulation, muscle contraction, and acetylcholine. Research on muscle contraction, in particular, is a crucial component, connecting studies of cellular physiology with broader clinical applications in cardiovascular and neuromuscular medicine.
2. Endocrinology
Endocrinology represents around 51.56% of the journal’s research coverage. BJP publishes studies exploring hormone regulation, metabolic pathways, and signaling mechanisms. Topics such as calcium signaling are closely linked to endocrine research, reflecting the journal’s emphasis on understanding molecular and cellular mechanisms underlying endocrine function and disorders.
3. Pharmacology
Pharmacology forms roughly 25.35% of BJP’s research output, integrating knowledge from anesthesia, neuroscience, immunology, and in vivo studies. The journal particularly emphasizes the pharmacological mechanisms of drugs, their receptor interactions, and therapeutic potential. Immunology-focused research within pharmacology often investigates inflammation and immune modulation, providing insights relevant for drug development and disease treatment.
4. Receptor Studies
BJP gives special attention to receptor biology, particularly the study of receptor antagonists. Research in this area explores the interaction of drugs with cellular receptors, contributing to the understanding of therapeutic mechanisms and the development of new pharmacological agents.
5. Biochemistry and Biophysics
Journal also publishes research in biochemistry and biophysics, often overlapping with molecular biology. Biophysical studies frequently focus on membrane potential and signaling pathways, offering insight into the fundamental processes that underpin pharmacological responses. These studies help bridge molecular mechanisms with physiological and clinical outcomes.
Indexing of the British Journal of Pharmacology
The British Journal of Pharmacology (BJP) is widely recognized and indexed in several reputable databases, reflecting its credibility, academic quality, and visibility in the scientific community. Being indexed ensures that the journal meets rigorous standards for editorial quality, peer review, and publication ethics.
Major Indexing Databases
The BJP is indexed in the following leading databases:
- UGC CARE – Recognized by the University Grants Commission (UGC) for maintaining high publication standards, ensuring authors receive academic credibility for research published in the journal.
- Scopus – A premier abstract and citation database of peer-reviewed literature, which allows researchers to track citations, analyze research impact, and ensure global discoverability of articles.
- Web of Science (Science Citation Index Expanded – SCIE) – Part of the Web of Science Core Collection, SCIE indexes high-quality scientific journals and tracks citation metrics. SCIE coverage reflects the journal’s strong influence in scientific research.
- PubMed – A globally trusted database for biomedical and life sciences research. Inclusion in PubMed ensures that BJP’s articles are easily accessible to the medical and pharmacology research community.
- Embase – A comprehensive biomedical and pharmacological database, enhancing the journal’s visibility in pharmacology, toxicology, and drug development research.
British Journal of Pharmacology Impact Factor 2025
The British Journal of Pharmacology (BJP) has a latest Impact Factor of 7.7, updated in June 2025.
Reflecting its continued prominence in the field of pharmacology. The Impact Factor measures how often, on average, articles published in the journal over the previous two years are cited in a given year, indicating the journal’s influence and academic relevance.
A higher IF demonstrates that BJP’s research is widely read and cited, making it a respected platform for authors seeking visibility and recognition.
Consistently ranked in Q1 among pharmacology journals, BJP remains a leading outlet for high-quality pharmacological research worldwide, influencing both researchers and institutions.
Journal Publication Time
The publication timeline for the British Journal of Pharmacology (BJP) varies depending on factors such as the complexity of the research, manuscript type, and the editorial team’s workload. Typically, the journal requests reviewers to submit their evaluations within 3–4 weeks, but actual review times can extend if reviewers face scheduling conflicts or if the manuscript requires additional scrutiny.
The speed of the review process also depends on the quality of the submission. Well-prepared manuscripts with clear methodology and adherence to journal guidelines often move through the peer-review process more quickly, while papers requiring major revisions may take longer.
Overall, the total time from submission to final publication can vary, but understanding these factors helps authors plan their research dissemination effectively.
How to Publish in the British Journal of Pharmacology
Research focuses on Pharmacology, Toxicology, or Pharmaceutics, you can submit your manuscript through the official website of the British Journal of Pharmacology (BJP). The journal accepts original research, reviews, commentaries, and correspondence that align with its scope.
Tips for Publishing in BJP
To increase the likelihood of acceptance, authors should carefully prepare their manuscript:
1. Select a Relevant Research Problem – Choose a topic that addresses current challenges or gaps in pharmacology, toxicology, or pharmaceutics. Ensure the research question is novel and significant.
2. Present a Clear Solution – Provide well-supported findings, backed by experimental data or robust analysis. Clearly explain how your research advances the field.
3. Design Your Paper Effectively – Structure your manuscript according to the journal’s guidelines, including proper sections such as introduction, methods, results, and discussion.
4. Make Your Manuscript Publication-Worthy – Ensure clarity, conciseness, and scientific rigor. Follow formatting, language, and ethical standards.
5. Write an Effective Results Section – Present data clearly, using tables, figures, and graphs where appropriate. Highlight key findings without overinterpretation.
6. Mind Your References – Cite relevant and up-to-date literature, following the journal’s reference style to enhance credibility and contextual relevance.
Acceptance Rate
The acceptance rate of a journal represents the ratio of published articles to submitted manuscripts. BJP maintains a competitive acceptance rate, reflecting its high standards and rigorous peer-review process. Authors can check the exact acceptance rate on the journal’s website or contact the editorial office for the most accurate information.
2025 Editorial Changes at the British Journal of Pharmacology (BJP)
In 2025, BJP has signalled a fresh phase of editorial evolution that aims to sharpen its scientific leadership and broaden its inclusivity. The journal — under the auspices of British Pharmacological Society (BPS) and published by John Wiley & Sons, Inc. — has initiated an open call to recruit new Senior Editors, with appointments set to begin January 2026.
These forthcoming additions to the editorial board reflect BJP’s commitment to expanding its subject‑area expertise: the 2026 intake seeks strong candidates especially in cancer pharmacology, neuropharmacology, and respiratory pharmacology, while remaining open to broad expertise across pharmacological disciplines.
The expanded board structure aligns with the journal’s 2025 drive for greater equity, diversity, and inclusion (EDI) — aiming to amplify voices from under‑represented regions and backgrounds, and to ensure diverse participation in peer review, editorial oversight, and authorship.
Through these changes, BJP not only renews its editorial leadership but also seeks to strengthen peer‑review quality, diversify scientific perspectives, and improve support for authors across the global pharmacology community.
FAQs
1. Can BJP manuscripts include negative or non-significant results?
Yes. BJP encourages publication of well-conducted studies regardless of whether results are positive or negative, as long as they provide scientific insight or advance pharmacological understanding.
2. Does BJP accept interdisciplinary studies outside classical pharmacology?
Yes. BJP welcomes research at the intersection of pharmacology, systems biology, neuroscience, immunology, and computational modeling, provided it contributes to mechanistic understanding or therapeutic insight.
3. Are preprints allowed before submission to BJP?
Yes. BJP permits submission of manuscripts previously posted on recognized preprint servers, but authors must declare this during submission.
4. How does BJP ensure reproducibility of published studies?
BJP promotes rigorous methodological reporting, including detailed protocols, statistical analyses, and data availability statements to enhance reproducibility and transparency.
5. Can early-career researchers serve as corresponding authors?
Yes. BJP does not restrict corresponding authorship based on career stage. Mentorship and adherence to submission guidelines are emphasized for smooth peer review.
6. Does BJP provide guidance for visual abstracts or graphical summaries?
Yes. BJP encourages graphical abstracts for clarity and broader dissemination, especially for complex pharmacological mechanisms or translational studies.
7. Are supplementary data files encouraged in BJP submissions?
Yes. Authors can include supplementary tables, figures, and datasets to provide additional context, experimental details, or extended analyses.
8. How does BJP handle corrections or retractions?
BJP follows strict editorial policies for corrections, errata, and retractions to maintain academic integrity, ensuring transparency and credibility in the published literature.
9. Can clinical trial data be submitted to BJP?
Yes. BJP accepts preclinical and clinical studies, provided they comply with ethical standards, registration requirements, and offer novel pharmacological insights.
10. Does BJP offer support for authors from underrepresented regions?
Yes. As part of its 2025 editorial inclusivity drive, BJP provides guidance, mentorship, and peer review support to authors from underrepresented countries or institutions.